CYP39A1 Antibody

What is CYP39A1 and what is its molecular function?

CYP39A1 is a poorly characterized metabolic enzyme belonging to the cytochrome P450 superfamily. It functions primarily as an oxysterol 7 alpha-hydroxylase that participates in the metabolism of 24 hydroxycholesterol (24OHC) . The gene is located on human chromosome 6 and contains 14 coding exons. Beyond its metabolic functions, CYP39A1 appears to play significant roles in inflammation and carcinogenesis, particularly in hepatocellular carcinoma where it demonstrates tumor suppressor properties . Recent evidence suggests CYP39A1 may influence cell growth regulation through modulation of signaling pathways including NF-κB and Nrf2 .

What is the subcellular localization of CYP39A1?

CYP39A1 is primarily localized in the cytoplasm of hepatocytes and hepatocellular carcinoma cells, with minimal expression in stromal cells . Immunohistochemical staining reveals cytoplasmic distribution with varying staining intensities that can be classified according to a four-tier grading system: absent (0), weak (1), moderate (2), and strong (3) . This cytoplasmic localization is consistent with its role as a metabolic enzyme involved in oxysterol processing and is an important consideration when designing cell fractionation protocols for CYP39A1 detection.

What are the optimal conditions for CYP39A1 antibody validation?

Proper validation of CYP39A1 antibodies requires multiple complementary approaches. Researchers should implement:

• Western blotting with appropriate positive controls (normal liver tissue) and negative controls

• Comparative analysis with mRNA expression data

• Immunohistochemical validation across multiple tissue types with known expression levels

For Western blotting validation, researchers have successfully used a primary antibody dilution of 1:1000, followed by incubation with HRP-conjugated IgG secondary antibody at 1:5000 dilution . Protein normalization should be performed against appropriate housekeeping proteins such as Vinculin (for tissue samples) or beta-tubulin (for cell lines and mouse models) . The detection of a single band at the expected molecular weight, with corresponding intensity patterns matching mRNA expression levels across samples, provides strong validation evidence.

How can researchers interpret contradictory CYP39A1 expression data?

When encountering contradictory CYP39A1 expression data, researchers should consider:

• Tissue heterogeneity - CYP39A1 expression can vary significantly across different regions of the same tissue

• Antibody specificity issues - Different antibodies may recognize different epitopes or isoforms

• Technical variations in sample preparation and detection methods

To resolve such contradictions, employ multi-platform validation comparing protein detection (IHC, Western blot) with mRNA quantification (qPCR, RNA-Seq). In previous studies, researchers validated CYP39A1 downregulation in HCC by combining multiple independent microarray datasets (GSE14520, GSE45267, GSE64041), TCGA data analysis, and direct measurement in fresh tissue samples using RT-PCR and Western blotting . This comprehensive approach revealed consistent downregulation of CYP39A1 in HCC despite variations in individual samples.

What are the best approaches for studying CYP39A1 variants using antibody-based methods?

Standard antibody-based methods may not distinguish between wild-type CYP39A1 and variant proteins with similar epitopes but different functional properties. Researchers should consider:

• Combining immunoprecipitation with mass spectrometry for variant identification

• Using variant-specific antibodies when available

• Complementing antibody detection with functional enzymatic assays

In studies of CYP39A1 variants associated with exfoliation syndrome, researchers successfully employed biochemical assays to classify 34 of 42 damaging CYP39A1 alleles as functionally deficient, with a median reduction in enzymatic activity of 94.4% compared to wild-type CYP39A1 . These functional assays provided critical information that antibody-based detection alone could not reveal about the variants' biological activity.

How can CYP39A1 antibodies be utilized in hepatocellular carcinoma research?

CYP39A1 antibodies serve multiple functions in HCC research:

• Biomarker detection - IHC staining of tumor tissues to evaluate CYP39A1 as a prognostic indicator

• Mechanistic studies - Protein detection following experimental manipulation of CYP39A1 expression

• Tumor classification - Stratification of HCC subtypes based on CYP39A1 expression patterns

Studies have demonstrated that CYP39A1 protein expression is significantly downregulated in HCC compared to adjacent normal tissues, with positive expression rates of 33.96% in HCC versus 88.05% in normal liver tissues . This differential expression correlates with clinical parameters, including tumor differentiation and patient survival. Researchers investigating CYP39A1 in HCC should employ a standardized IHC scoring system, categorizing staining as negative (score ≤1) or positive (score >1) to maintain consistency with published literature .

What methodological considerations are important when investigating CYP39A1's role in exfoliation syndrome?

When investigating CYP39A1's role in exfoliation syndrome, researchers should:

• Combine genetic analysis with protein expression studies

• Implement immunohistochemical analysis with appropriate antibodies on both cryosections and paraffin-embedded sections

• Consider co-staining approaches to examine relationships with cholesterol metabolism

Research has established that CYP39A1 variants are significantly associated with exfoliation syndrome, with 5.2% of affected individuals carrying damaging CYP39A1 alleles compared to 3.1% of controls . Methodologically, quantitative real-time PCR revealed 47% lower CYP39A1 transcript expression in ciliary body tissues from individuals with exfoliation syndrome compared to controls . For protein detection, immunohistochemical analysis should incorporate heat-induced antigen retrieval for optimal results, and consider complementary filipin staining to visualize esterified and free unesterified cholesterol .

How do translational modifications affect CYP39A1 antibody detection in disease states?

Post-translational modifications of CYP39A1 may affect epitope accessibility and antibody binding affinity, potentially confounding detection in disease states. Researchers should:

• Utilize antibodies targeting different epitopes when possible

• Consider phosphorylation-specific or other modification-specific antibodies if relevant

• Employ denaturing and non-denaturing conditions in parallel to assess structural impacts on detection

While the search results don't specifically address post-translational modifications of CYP39A1, research on other cytochrome P450 family members suggests these modifications may influence both function and detection. When investigating CYP39A1 in HCC, for example, researchers observed variations in immunoreactivity that could potentially reflect not just expression differences but also conformational or post-translational changes .

What are optimal protocols for CYP39A1 immunohistochemistry in liver tissues?

For optimal CYP39A1 immunohistochemistry in liver tissues, follow these guidelines:

• Tissue preparation: Use formalin-fixed, paraffin-embedded (FFPE) sections with appropriate antigen retrieval techniques

• Antibody dilution: Start with 1:1000 dilution of primary antibody (adjust based on specific antibody characteristics)

• Signal development: Employ a four-tier grading system (0=absent, 1=weak, 2=moderate, 3=strong) for consistent scoring

To enhance reliability, involve multiple independent pathologists in evaluation, with a third review when score differences ≥2 occur . For research contexts requiring higher sensitivity, consider signal amplification methods or fluorescent secondary antibodies. CYP39A1 staining should be evaluated specifically in hepatocytes rather than stromal cells, focusing on cytoplasmic localization .

What are the recommended procedures for CYP39A1 Western blotting?

For effective CYP39A1 Western blotting:

This protocol has been successfully implemented in studies examining CYP39A1 expression in both fresh human liver tissues and experimental cell models . For whole tissue analysis, ensure samples are adequately homogenized and consider enriching for cellular fractions where CYP39A1 is most abundant to enhance detection sensitivity.

How can researchers troubleshoot weak or non-specific CYP39A1 antibody staining?

When encountering issues with CYP39A1 antibody staining:

• For weak signals:

  • Optimize antigen retrieval methods (try heat-induced epitope retrieval)

  • Increase antibody concentration or incubation time

  • Employ signal amplification systems

  • Check sample quality and storage conditions

• For non-specific staining:

  • Increase blocking duration and concentration

  • Try alternative blocking reagents (BSA, normal serum, casein)

  • Implement additional washing steps

  • Validate antibody specificity using knockout/knockdown controls

• For inconsistent results:

  • Standardize tissue processing and fixation protocols

  • Prepare fresh antibody dilutions

  • Include positive and negative controls in each experiment

  • Consider lot-to-lot variations in antibody performance

Studies have demonstrated that CYP39A1 detection requires careful optimization, particularly in diseased tissues where expression levels may be significantly reduced compared to normal controls .

What approaches can be used to quantify CYP39A1 expression levels accurately?

For accurate quantification of CYP39A1 expression:

• Protein level quantification:

  • Densitometric analysis of Western blots with appropriate normalization

  • Digital image analysis of IHC staining with standardized scoring systems

  • Flow cytometry for cell-by-cell quantification in suspension samples

• Transcript level quantification:

  • Real-time PCR with validated reference genes

  • RNA-Seq analysis with appropriate depth of coverage

  • Validation across multiple independent datasets (e.g., GEO, TCGA)

• Integrated approaches:

  • Correlation analysis between protein and mRNA levels

  • Multi-platform validation across different quantification methods

  • Functional correlation with enzymatic activity assays